These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19225451)

  • 1. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
    Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
    Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.
    Spreafico M; Lodigiani C; van Leeuwen Y; Pizzotti D; Rota LL; Rosendaal F; Mannucci PM; Peyvandi F
    Pharmacogenomics; 2008 Sep; 9(9):1237-50. PubMed ID: 18781852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
    Verstuyft C; Delavenne X; Rousseau A; Robert A; Tod M; Diquet B; Lebot M; Jaillon P; Becquemont L
    Clin Pharmacokinet; 2012 Jan; 51(1):41-53. PubMed ID: 22149257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
    Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
    J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.
    Allabi AC; Horsmans Y; Alvarez JC; Bigot A; Verbeeck RK; Yasar U; Gala JL
    Eur J Drug Metab Pharmacokinet; 2012 Jun; 37(2):125-32. PubMed ID: 21811894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
    Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
    Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.
    Montes R; Ruiz de Gaona E; Martínez-González MA; Alberca I; Hermida J
    Br J Haematol; 2006 Apr; 133(2):183-7. PubMed ID: 16611310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
    Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
    Bodin L; Verstuyft C; Tregouet DA; Robert A; Dubert L; Funck-Brentano C; Jaillon P; Beaune P; Laurent-Puig P; Becquemont L; Loriot MA
    Blood; 2005 Jul; 106(1):135-40. PubMed ID: 15790782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.
    Verde Z; Ruiz JR; Santiago C; Valle B; Bandrés F; Calvo E; Lucía A; Gómez Gallego F
    PLoS One; 2010 Jun; 5(6):e11210. PubMed ID: 20585445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
    Sychev DA; Ignat'ev IV; Kropacheva ES; Emel'ianov NV; Milovanova VV; Naumova IuA; Kosovskaia AV; Dobrovol'skiĭ OB; Tashenova AI; Panchenko EP; Kukes VG
    Vestn Ross Akad Med Nauk; 2011; (3):7-10. PubMed ID: 21544933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9.
    Rettie AE; Farin FM; Beri NG; Srinouanprachanh SL; Rieder MJ; Thijssen HH
    Br J Clin Pharmacol; 2006 Nov; 62(5):617-20. PubMed ID: 16869821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
    Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
    van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.